Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05896800
Other study ID # 2023-COPD-002
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 7, 2023
Est. completion date June 30, 2024

Study information

Verified date February 2024
Source The First Affiliated Hospital with Nanjing Medical University
Contact Linfu Zhou, Doctor
Phone +8613611573618
Email linfu.zhou@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the influence of exercise capacity and safety of iNO at doses of 10 ppm or 40 ppm for 2 hours per day after continuous treatment for one week, which is of great significance for finding safe and effective methods for treating COPD.


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age = 40 years, = 75 years; 2. Previous smoking history = 10 pack-years, and had stopped smoking for one month before study entry; 3. Met the diagnosis criteria of moderate and severe COPD: a post-bronchodilator FEV1/FVC < 0.7, and 30%< FEV1 < 80% predicted; 4. Signed informed consent and performed all the study mandated procedures. Exclusion Criteria: 1. Pregnant or lactating women; 2. Current or recent month user of nicotine-like substances (including nicotine patches, etc.); 3. A diagnosis of asthma or other non-COPD respiratory disease, in the opinion of the Investigator; 4. Lack of patency of nares upon physical examination; 5. Experienced during the last month an exacerbation requiring start of or increase in systemic oral corticosteroid therapy; 6. Left ventricular systolic dysfunction: left ventricular ejection fraction (LVEF) < 50%; 7. Clinically significant valvular heart disease, including aortic valvular disease (moderate or severe aortic stenosis or regurgitation) and/or mitral valve disease (moderate or severe mitral stenosis or regurgitation), or status post mitral valve replacement; 8. Use within 30 days of screening or current use of approved pulmonary hypertension medications such as sildenafil, bosentan or prostacyclines; 9. Use of investigational drugs or devices within 30 days prior to enrollment into the study; 10. Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Nitric Oxide Generation and Delivery System
The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.

Locations

Country Name City State
China The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
The First Affiliated Hospital with Nanjing Medical University Novlead Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiopulmonary Exercise Test: Maximal oxygen uptake(VO2max) Change in VO2max from Baseline after treatment with iNO Baseline, Day 7
Primary Cardiopulmonary Exercise Test: Minute ventilation-to-carbon dioxide output(VE/VCO2) Change in VE/VCO2 from Baseline after treatment with iNO Baseline, Day 7
Primary Cardiopulmonary Exercise Test: Borg score Change in Borg score from Baseline after treatment with iNO Baseline, Day 7
Primary Cardiopulmonary Exercise Test: oxygen uptake/work (?VO2/?W) ratio Change in ?VO2/?W ratio from Baseline after treatment with iNO Baseline, Day 7
Secondary Pulmonary function:Forced expiratory volume in 1 second(FEV1) Change in FEV1 from Baseline after treatment with iNO Baseline, Day 7
Secondary Pulmonary function: Forced vital capacity (FVC) Change in FVC from Baseline after treatment with iNO Baseline, Day 7
Secondary Pulmonary function:FEV1/FVC Change in FEV1/FVC from Baseline after treatment with iNO Baseline, Day 7
Secondary Life quality and symptom severity questionnaires: COPD assessment test (CAT) Change in CAT scores (0-40 scores, higher scores mean a worse outcome) from Baseline after treatment with iNO Baseline, Day 7
Secondary Life quality and symptom severity questionnaires: Modified Medical Research Council (mMRC) Dyspnea Scale Change in (mMRC) Dyspnea Scale scores (0-4 scores, higher scores mean a worse outcome) from Baseline after treatment with iNO Baseline, Day 7
Secondary Six-minute walk test Change in exercise capacity from Baseline after treatment with iNO: the distance of six-minute walk test Baseline, Day 7
Secondary Adverse events Incidence of adverse events = Number of subjects with adverse events/Total number of subjects in treatment×100% Baseline up to Day 7
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy